

Leishmaniasis

CHINA

2014
Published in July 2016

Country General Information (WHO, 2013)

Total population:	1,393,337,000	Age group <15>14 years, %:	18% / 82%
Gender (% F/M):	48.2% / 51.8%	Life expectancy at birth in years (F/M):	77 / 74
GDP (PPP int \$):	11 850	Number of 1st sub-national administrative level divisions, name:	34, Province
Income status:	Upper middle		

Epidemiology


	VL	CL	PKDL	MCL
Endemicity status:	Endemic	Endemic	Non endemic	Non endemic
Number of new cases (incidence):	294	No data	N/A	0
Number of relapse cases:	No data	No data	N/A	0
Total number of cases:	294	No data	N/A	0
Imported cases (n, %):	2 1%	No data	No data	N/A
Gender distribution (% F):	45%	No data	N/A	N/A
Age group distribution (% <5/5-14/>14):	(64/7/30)	No data	N/A	N/A
Incidence rate (cases/10 000 population in endemic areas):	0.01	No data	N/A	N/A
Endemic 1st sub-national administrative level divisions for VL or CL (n):	6	No data	N/A	N/A
Population at risk ¹ (% n/total):	16% (229570000 / 1393337000)	No data	N/A	N/A
Was there any outbreak?	Yes	No	N/A	N/A
Number of new ² foci:	294	294	N/A	N/A

N/A = not applicable VL = visceral leishmaniasis CL = cutaneous leishmaniasis PKDL = post-kala-azar dermal leishmaniasis MCL = mucocutaneous leishmaniasis


Monthly distribution of new cases January-December

2014	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	13	9	15	9	14	18	19	14	25	41	58	59
CL	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data



Number of new CL cases reported by month in 2013 and 2014*



Number of new (primary) VL cases reported by month in 2013 and 2014



Incidence rate/10 000 population and number of new CL (left) and new (primary) VL (right) cases from 1998 to



¹ Defined as "Number of people living in 1st sub-national administrative level endemic areas"


* Data not available

² For this reporting period, an area at the 1st sub-national administrative level reporting cases for the first time ever

Distribution of new CL (left) and new (primary) VL (right) cases

No data for CL

Incidence of VL in China in 2014 at province level per 10 000 population



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
Map production: WHO/HTM/NTD/IDM

Control and surveillance

Year Leishmaniasis National Control Programme (LNCP) was established:	Not available	Year latest national guidelines were published:	Not available
Type of surveillance:	Not available	Is leishmaniasis a notifiable disease (mandatory reporting)?	Not available
Is there a vector control programme?	Not available	Is there a reservoir host control programme?	Not available
Type of insecticide used for IRS:	Not available	Number of leishmaniasis health facilities:	Not available

Diagnosis

	VL	CL	PKDL	MCL
Number of people screened actively for:	No data	No data	N/A	No data
Number of people screened passively for:	No data	No data	N/A	No data
VL cases diagnosed by RDT* (%, # RDT+/total VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT* (%, # RDT+/total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides +/total cases):	No data	No data	N/A	N/A
Proportion of positive slides (%, # slides +/total slides):	No data	No data	N/A	N/A
Cases diagnosed clinically (%, # clinical cases/total cases):	15% (45/294)	No data	N/A	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	N/A	N/A

* These indicators apply only for primary VL cases

VL = visceral leishmaniasis

CL = cutaneous leishmaniasis

PKDL = post-kala-azar dermal leishmaniasis

N/A = not applicable

RDT = rapid diagnostic test

HIV = human immunodeficiency virus

MCL = mucocutaneous leishmaniasis

Treatment and medicines

Is treatment provided free of charge in the public sector?	Not available
Antileishmanial medicines included in the national List of Essential Medicines:	Not available

TREATMENT OUTCOME

	VL
Proportion of relapse cases: ⁴	No data
Initial cure rate:	No data
Failure ⁵ rate:	No data
Case-fatality rate:	0.3% (1/294)

⁴ A relapse case in this country is defined as: No definition available

⁵ A failure case in this country is defined as: No definition available

Data source: Ministry of Health, People's Republic of China
© WHO 2014. All rights reserved.